International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.15 and traded as high as $0.17. International Stem Cell shares last traded at $0.17, with a volume of 3,400 shares trading hands.
International Stem Cell Price Performance
The stock has a 50-day simple moving average of $0.17 and a 200-day simple moving average of $0.15. The stock has a market cap of $1.36 million, a P/E ratio of -2.83 and a beta of 0.07.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last released its earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $2.32 million during the quarter.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Featured Stories
- Five stocks we like better than International Stem Cell
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
